Non-Hodgkin Lymphoma | Specialty

Risk Stratifying Patients With Follicular Lymphoma

August 15th 2017

Follicular Lymphoma: Diagnosis and Staging

August 15th 2017

Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

August 10th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Higher Bortezomib Doses Linked to Longer OS in MCL

August 10th 2017

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

SF3B1 Mutation Associated With Poor Survival in CLL

August 8th 2017

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

MRD Associated With Poorer Survival Following ASCT in MCL

August 7th 2017

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

August 3rd 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

FDA Awards Acalabrutinib Priority Review in MCL

August 2nd 2017

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

FDA Grants Acalabrutinib Breakthrough Designation in MCL

August 2nd 2017

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

EU Approval Sought for Axicabtagene Ciloleucel in Non-Hodgkin Lymphoma

August 1st 2017

Kite Pharma has submitted a Marketing Authorization Application to the European Medicines Agency for axicabtagene ciloleucel (axi-cel) to treat 3 forms of non-Hodgkin lymphoma.

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

July 31st 2017

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Emerging Agents for Mantle Cell Lymphoma

July 26th 2017

Acalabrutinib for Treating Mantle Cell Lymphoma

July 26th 2017

Ongoing Challenges in Treating Mantle Cell Lymphoma

July 26th 2017

Treating Relapsed/Refractory Mantle Cell Lymphoma

July 26th 2017

Role of Maintenance Therapy in Mantle Cell Lymphoma

July 26th 2017

Response Assessment in Mantle Cell Lymphoma

July 26th 2017

Options for Upfront Therapy in MCL

July 26th 2017

Induction Therapy for MCL

July 26th 2017

Risk Assessment and Prognosis in MCL

July 26th 2017